Back to top

Analyst Blog

Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report) and Monsanto Company (MON - Analyst Report) recently formed a strategic alliance to implement biological technologies in the field of agriculture. As per the alliance, Alnylam’s broad RNAi-based (ribo nucleic acid interference) intellectual property (IP) and proprietary technologies along with Monsanto’s new BioDirect technology will help deliver innovative biological solutions to farmers.

The Agreement

As per the terms of the agreement, Monsanto, a leading global provider of technology-based solutions and agricultural products, will acquire worldwide, exclusive rights to use Alnylam’s technologies in the field of agriculture. Monsanto will be able to grant sub-licenses as well.

Alnylam will receive $29.2 million in upfront payments, along with milestone payments and other additional funding from Monsanto. The agreement also allows Alnylam to receive royalty payments on the products that will utilize the company’s platform technology and IP. With this alliance, Monsanto becomes Alnylam’s strategic partner in agriculture for the next 10 years.

Our Take

We are pleased to see Alnylam stepping beyond its primary focus area. This will promote broader use of the company’s technology. Alnylam had earlier entered into key partnerships with companies like Medtronic, Inc. (MDT - Analyst Report), Novartis AG (NVS - Analyst Report), Biogen Idec Inc. (BIIB - Analyst Report), Roche Holding AG (RHHBY - Analyst Report), Takeda Pharmaceutical Company Limited (TKPYY) and Cubist Pharmaceuticals Inc. (CBST - Analyst Report) to share its RNAi know-how.

The Monsanto alliance will fetch upfront, milestone payments and other additional funding that will strengthen the company’s cash position. Alnylam exited the second quarter of 2012 with cash, cash equivalents and total marketable securities of around $293 million.

Besides these agreements, Alnylam makes use of its potentially revolutionary RNAi technology for the treatment of a wide array of diseases. The company expects to have five such RNAi therapeutic programs in advanced clinical development by the end of 2015. We expect investor focus to remain on the company’s pipeline going forward.

The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%